AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) shares were up 4.1% during mid-day trading on Thursday . The stock traded as high as $4.7491 and last traded at $4.55. 82,457 shares were traded during trading, an increase of 426% from the average session volume of 15,685 shares. The stock had previously closed at $4.37.
AlloVir Price Performance
The firm has a market capitalization of $22.95 million, a price-to-earnings ratio of -0.22 and a beta of 0.63. The business has a fifty day moving average price of $5.25 and a two-hundred day moving average price of $7.38.
About AlloVir
AlloVir, Inc is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company’s proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses.
AlloVir’s pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings.
Featured Articles
- Five stocks we like better than AlloVir
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
